Last 12 months
Inside the activity.
0 purchase rows · 11 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 25, 2021 Filed May 26, 2021 15:15 UTC |
PARRISH MARK WDirector
|
GrantCommon Stock | 1,323 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-005927 · edgar.xml · nonDerivative · entry 2 PARRISH MARK W · CIK 0001236452 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,558 F1 · shares: Grant of restricted shares in consideration of services as a Board Member. Shares shall vest in full on the date of the Company's 2022 Annual Meeting of Stockholders. Read SEC document |
| May 25, 2021 Filed May 26, 2021 15:15 UTC |
WHITE SARA JDirector
|
GrantCommon Stock | 1,257 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-005926 · edgar.xml · nonDerivative · entry 2 WHITE SARA J · CIK 0001227559 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,992 F1 · shares: Grant of restricted shares in consideration of services as a Board Member. Shares shall vest in full on the date of the Company's 2022 Annual Meeting of Stockholders. Read SEC document |
| May 18, 2021 Filed May 18, 2021 21:09 UTC |
Kuipers Peter J.Executive V P& CFO
|
SaleCommon Ttock | 457 | $136.53 | $62,394.21 |
DisclosureSEC source: 0001179110-21-005513 · edgar.xml · nonDerivative · entry 4 Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,454 F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $136.05 to $136.74. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| May 18, 2021 Filed May 18, 2021 21:09 UTC |
Kuipers Peter J.Executive V P& CFO
|
SaleCommon Stock | 1,231 | $135.76 | $167,120.56 |
DisclosureSEC source: 0001179110-21-005513 · edgar.xml · nonDerivative · entry 3 Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,911 F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $134.93 to $135.76. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| May 18, 2021 Filed May 18, 2021 21:09 UTC |
Kuipers Peter J.Executive V P& CFO
|
SaleCommon Stock | 707 | $134.49 | $95,084.43 |
DisclosureSEC source: 0001179110-21-005513 · edgar.xml · nonDerivative · entry 2 Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,142 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $133.78 to $134.49. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| May 04, 2021 Filed May 5, 2021 15:16 UTC |
MELLON CHRISTINE MARIEEVP, Chief People Officer
|
PurchaseCommon Stock | 43 | $137.64 | $5,918.52 |
DisclosureSEC source: 0001179110-21-004889 · edgar.xml · nonDerivative · entry 1 MELLON CHRISTINE MARIE · CIK 0001848442 · EVP, Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,510 F1 · shares: Omnicell shares purchased in open market and held at Fidelity. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 20:18 UTC |
SPEARS JOSEPH BRIANChief Accounting Officer & VP
|
Tax withholdingCommon Stock | 185 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-003455 · edgar.xml · nonDerivative · entry 2 SPEARS JOSEPH BRIAN · CIK 0001729964 · Chief Accounting Officer & VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,792 F1 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 23:11 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
Tax withholdingCommon Stock | 4,422 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002733 · edgar.xml · nonDerivative · entry 4 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,474 F3 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 23:11 UTC |
JOHNSTON DAN SEVP & Chief Legal & Admin
|
Tax withholdingCommon Stock | 383 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002732 · edgar.xml · nonDerivative · entry 2 JOHNSTON DAN S · CIK 0001271802 · EVP & Chief Legal & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,928 F1 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 23:10 UTC |
Kuipers Peter J.Executive V P& CFO
|
Tax withholdingCommon Stock | 575 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002730 · edgar.xml · nonDerivative · entry 2 Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,849 F2 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 23:10 UTC |
Seidelmann Scott PeterEVP, Chief Commercial Officer
|
Tax withholdingCommon Stock | 771 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002729 · edgar.xml · nonDerivative · entry 2 Seidelmann Scott Peter · CIK 0001736895 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,147 F1 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 21:38 UTC |
MELLON CHRISTINE MARIEEVP, Chief People Officer
|
GrantCommon Stock | 6,595 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002879 · edgar.xml · nonDerivative · entry 2 MELLON CHRISTINE MARIE · CIK 0001848442 · EVP, Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,467 F2 · shares: The Performance-based restricted stock unit awards vest as to 25% of the shares on the date of the Compensation Committee meeting in 2022 when the Committee reviews the performance-based metrics and determines if they were met or not with the remaining shares vesting on a semi-annual basis over a period of thirty-six months commencing on June 15, 2022 if the Company meets certain stock performance objectives compared to the NASDAQ Healthcare Index. The actual number of performance-based stock awards that vest may be 0%, 50% or 100% or 150% Or 200% of the numbers reflected above, depending upon the Company's performance. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 21:38 UTC |
MELLON CHRISTINE MARIEEVP, Chief People Officer
|
GrantCommon Stock | 7,872 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002879 · edgar.xml · nonDerivative · entry 1 MELLON CHRISTINE MARIE · CIK 0001848442 · EVP, Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,872 F1 · shares: RSU: Restricted Stock Units shall vest semiannually on 6/15 and 12/15 for a period of 4 years. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:43 UTC |
Seidelmann Scott PeterEVP, Chief Commercial Officer
|
GrantCommon Stock | 9,520 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001587 · edgar.xml · nonDerivative · entry 3 Seidelmann Scott Peter · CIK 0001736895 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,918 F2 · shares: The Performance-based restricted stock unit awards vest as to 25% of the shares on the date of the Compensation Committee meeting in 2022 when the Committee reviews the performance-based metrics and determines if they were met or not with the remaining shares vesting on a semi-annual basis over a period of thirty-six months commencing on June 15, 2022 if the Company meets certain stock performance objectives compared to the NASDAQ Healthcare Index. The actual number of performance based stock awards that vest may be 0%, 50% or 100% or 150% or 200% of the numbers reflected above, depending upon the Company's performance. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:43 UTC |
Seidelmann Scott PeterEVP, Chief Commercial Officer
|
GrantCommon Stock | 11,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001587 · edgar.xml · nonDerivative · entry 2 Seidelmann Scott Peter · CIK 0001736895 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,398 F1 · shares: RSU: Restricted Stock Units shall vest semiannually on 6/15 and 12/15 for a period of 4 years Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:43 UTC |
Kuipers Peter J.Executive V P& CFO
|
GrantCommon Stock | 11,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001586 · edgar.xml · nonDerivative · entry 3 Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,713 F2 · shares: RSU: Restricted Stock Units shall vest semiannually on 6/15 and 12/15 for a period of 4 years Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:43 UTC |
Kuipers Peter J.Executive V P& CFO
|
GrantCommon Stock | 9,520 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001586 · edgar.xml · nonDerivative · entry 2 Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,363 F1 · shares: The Performance-based restricted stock unit awards vest as to 25% of the shares on the date of the Compensation Committee meeting in 2022 when the Committee reviews the performance-based metrics and determines if they were met or not with the remaining shares vesting on a semi-annual basis over a period of thirty-six months commencing on June 15, 2022 if the Company meets certain stock performance objectives compared to the NASDAQ Healthcare Index. The actual number of performance based stock awards that vest may be 0%, 50% or 100% or 150% or 200% of the numbers reflected above, depending upon the Company's performance. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:42 UTC |
JOHNSTON DAN SEVP & Chief Legal & Admin
|
GrantCommon Stock | 4,760 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001585 · edgar.xml · nonDerivative · entry 3 JOHNSTON DAN S · CIK 0001271802 · EVP & Chief Legal & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,164 F2 · shares: The Performance-based restricted stock unit awards vest as to 25% of the shares on the date of the Compensation Committee meeting in 2022 when the Committee reviews the performance-based metrics and determines if they were met or not with the remaining shares vesting on a semi-annual basis over a period of thirty-six months commencing on June 15, 2022 if the Company meets certain stock performance objectives compared to the NASDAQ Healthcare Index. The actual number of performance based stock awards that vest may be 0%, 50% or 100% or 150% or 200% of the numbers reflected above, depending upon the Company's performance. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:42 UTC |
JOHNSTON DAN SEVP & Chief Legal & Admin
|
GrantCommon Stock | 5,675 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001585 · edgar.xml · nonDerivative · entry 2 JOHNSTON DAN S · CIK 0001271802 · EVP & Chief Legal & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,405 F1 · shares: RSU: Restricted Stock Units shall vest semiannually on 6/15 and 12/15 for a period of 4 years Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:40 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
GrantCommon Stock | 20,715 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001582 · edgar.xml · nonDerivative · entry 5 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,352 F4 · shares: The Performance-based restricted stock unit awards vest as to 25% of the shares on the date of the Compensation Committee meeting in 2022 when the Committee reviews the performance-based metrics and determines if they were met or not with the remaining shares vesting on a semi-annual basis over a period of thirty-six months commencing on June 15, 2022 if the Company meets certain stock performance objectives compared to the NASDAQ Healthcare Index. The actual number of performance based stock awards that vest may be 0%, 50% or 100% or 150% Or 200% of the numbers reflected above, depending upon the Company's performance. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:40 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
GrantCommon Stock | 20,715 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001582 · edgar.xml · nonDerivative · entry 4 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,116 F3 · shares: RSU: Restricted Stock Units shall vest semiannually on 6/15 and 12/15 for a period of 4 years Read SEC document |
| January 04, 2021 Filed Jan 4, 2021 22:18 UTC |
Seim Robin GeneDirector
|
SaleCommon Stock | 1,319 | $119.62 | $157,778.78 |
DisclosureSEC source: 0001179110-21-000065 · edgar.xml · nonDerivative · entry 2 Seim Robin Gene · CIK 0001351911 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,558 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan adopted by the reporting person on August 17, 2020. F1 · price: The price reported in Column 4 is the exact price of $119.62. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 21:16 UTC |
Seidelmann Scott PeterEVP, Chief Commercial Officer
|
SaleCommon Stock | 100 | $116.05 | $11,605.00 |
DisclosureSEC source: 0001179110-20-012048 · edgar.xml · nonDerivative · entry 4 Seidelmann Scott Peter · CIK 0001736895 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,048 F3 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. F4 · shares: The price reported in Column 4 is the average price of $116.05. The sold shares for the exact price. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · price: The price reported in Column 4 is the average price of $116.05. The sold shares for the exact price. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 21:16 UTC |
Seidelmann Scott PeterEVP, Chief Commercial Officer
|
SaleCommon Stock | 1,725 | $115.68 | $199,551.11 |
DisclosureSEC source: 0001179110-20-012048 · edgar.xml · nonDerivative · entry 3 Seidelmann Scott Peter · CIK 0001736895 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,148 F3 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. F2 · shares: The price reported in Column 4 is the average price of $115.6818. The sold price range between $115.02 to $116.00. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · price: The price reported in Column 4 is the average price of $115.6818. The sold price range between $115.02 to $116.00. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 21:16 UTC |
Seidelmann Scott PeterEVP, Chief Commercial Officer
|
SaleCommon Stock | 300 | $114.13 | $34,239.00 |
DisclosureSEC source: 0001179110-20-012048 · edgar.xml · nonDerivative · entry 2 Seidelmann Scott Peter · CIK 0001736895 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,873 F3 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. F1 · shares: The price reported in Column 4 is the average price of $114.13. The sold price range between $113.95 to $114.49. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · price: The price reported in Column 4 is the average price of $114.13. The sold price range between $113.95 to $114.49. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 17:57 UTC |
Kuipers Peter J.Executive V P& CFO
|
Tax withholdingCommon Stock | 3,747 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-011973 · edgar.xml · nonDerivative · entry 2 Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,843 F1 · price: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 17:56 UTC |
JOHNSTON DAN SEVP & Chief Legal & Admin
|
Tax withholdingCommon Stock | 2,058 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-011972 · edgar.xml · nonDerivative · entry 2 JOHNSTON DAN S · CIK 0001271802 · EVP & Chief Legal & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,729 F1 · price: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 17:56 UTC |
Ngo Nhat HEVP, Marketing, S & B D
|
Tax withholdingCommon Stock | 2,280 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-011971 · edgar.xml · nonDerivative · entry 2 Ngo Nhat H · CIK 0001305020 · EVP, Marketing, S & B D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,818 F1 · price: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 17:55 UTC |
Seidelmann Scott PeterEVP, Chief Commercial Officer
|
Tax withholdingCommon Stock | 2,087 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-011970 · edgar.xml · nonDerivative · entry 2 Seidelmann Scott Peter · CIK 0001736895 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,173 F1 · price: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 17:55 UTC |
SPEARS JOSEPH BRIANChief Accounting Officer & VP
|
Tax withholdingCommon Stock | 372 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-011969 · edgar.xml · nonDerivative · entry 2 SPEARS JOSEPH BRIAN · CIK 0001729964 · Chief Accounting Officer & VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,621 F1 · price: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 17:54 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
Tax withholdingCommon Stock | 10,236 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-011968 · edgar.xml · nonDerivative · entry 4 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,880 F3 · price: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| December 09, 2020 Filed Dec 9, 2020 22:23 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
Exercise / conversionStock Options NQ (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $27.20 | $0.00 |
DisclosureSEC source: 0001179110-20-011797 · edgar.xml · derivative · entry 10 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2026-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan adopted by the reporting person on February 20, 2020. Read SEC document |
| December 09, 2020 Filed Dec 9, 2020 22:23 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
Exercise / conversionStock Options NQ (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $34.02 | $0.00 |
DisclosureSEC source: 0001179110-20-011797 · edgar.xml · derivative · entry 9 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2025-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan adopted by the reporting person on February 20, 2020. Read SEC document |
| December 09, 2020 Filed Dec 9, 2020 22:23 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
SaleCommon Stock | 100 | $124.75 | $12,475.00 |
DisclosureSEC source: 0001179110-20-011797 · edgar.xml · nonDerivative · entry 8 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,116 F7 · price: The price reported in Column 4 is the exact price of $124.75. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 09, 2020 Filed Dec 9, 2020 22:23 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
SaleCommon Stock | 9,586 | $124.12 | $1,189,788.44 |
DisclosureSEC source: 0001179110-20-011797 · edgar.xml · nonDerivative · entry 7 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,216 F3 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan adopted by the reporting person on February 20, 2020. F5 · price: The price reported in Column 4 is the average price of $124.1173. The sold price range between $123.75 to $124.70. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 09, 2020 Filed Dec 9, 2020 22:23 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
SaleCommon Stock | 1,225 | $121.22 | $148,492.30 |
DisclosureSEC source: 0001179110-20-011797 · edgar.xml · nonDerivative · entry 6 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,802 F3 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan adopted by the reporting person on February 20, 2020. F6 · price: The price reported in Column 4 is the average price of $121.2182. The sold price range between $121.00 to $121.41. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 09, 2020 Filed Dec 9, 2020 22:23 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
SaleCommon Stock | 14,089 | $120.34 | $1,695,485.76 |
DisclosureSEC source: 0001179110-20-011797 · edgar.xml · nonDerivative · entry 5 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,027 F3 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan adopted by the reporting person on February 20, 2020. F4 · price: The price reported in Column 4 is the average price of $120.3411. The sold price range between $120.00 to $120.95. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 09, 2020 Filed Dec 9, 2020 22:23 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
Exercise / conversionCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-011797 · edgar.xml · nonDerivative · entry 4 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,116 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan adopted by the reporting person on February 20, 2020. Read SEC document |
| December 08, 2020 Filed Dec 8, 2020 21:53 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
Exercise / conversionStock Options NQ (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $34.02 | $0.00 |
DisclosureSEC source: 0001179110-20-011775 · edgar.xml · derivative · entry 8 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,500 shares Expires 2025-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan adopted by the reporting person on February 20, 2020. Read SEC document |
| December 08, 2020 Filed Dec 8, 2020 21:53 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
SaleCommon Stock | 651 | $111.07 | $72,307.48 |
DisclosureSEC source: 0001179110-20-011775 · edgar.xml · nonDerivative · entry 7 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,116 F3 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan adopted by the reporting person on February 20, 2020. F5 · price: The price reported in Column 4 is the average price of $111.0714. The sold price range between $111.01 to $111.11. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 08, 2020 Filed Dec 8, 2020 21:53 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
Exercise / conversionCommon Stock | 651 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-011775 · edgar.xml · nonDerivative · entry 6 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,767 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan adopted by the reporting person on February 20, 2020. Read SEC document |
| December 08, 2020 Filed Dec 8, 2020 21:53 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
SaleCommon Stock | 16,849 | $110.54 | $1,862,410.95 |
DisclosureSEC source: 0001179110-20-011775 · edgar.xml · nonDerivative · entry 5 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,116 F3 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan adopted by the reporting person on February 20, 2020. F4 · price: The price reported in Column 4 is the average price of $110.5354. The sold price range between $110.00 to $110.99. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 08, 2020 Filed Dec 8, 2020 21:53 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
Exercise / conversionCommon Stock | 16,849 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-011775 · edgar.xml · nonDerivative · entry 4 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,965 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan adopted by the reporting person on February 20, 2020. Read SEC document |
| November 23, 2020 Filed Nov 23, 2020 23:24 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
Exercise / conversionStock Options NQ (Right to Buy) · Derivative | 12,600 | $0.00 Strike: $34.02 | $0.00 |
DisclosureSEC source: 0001179110-20-011291 · edgar.xml · derivative · entry 9 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,600 shares Expires 2025-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan adopted by the reporting person on February 20, 2020. Read SEC document |
| November 23, 2020 Filed Nov 23, 2020 23:24 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
SaleCommon Stock | 12,600 | $105.40 | $1,328,029.92 |
DisclosureSEC source: 0001179110-20-011291 · edgar.xml · nonDerivative · entry 7 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,116 F3 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan adopted by the reporting person on February 20, 2020. F5 · price: The price reported in Column 4 is the average price of $105.3992. The sold price range between $105.0050 to $105.9200. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 23, 2020 Filed Nov 23, 2020 23:24 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
Exercise / conversionCommon Stock | 12,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-011291 · edgar.xml · nonDerivative · entry 6 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,716 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan adopted by the reporting person on February 20, 2020. Read SEC document |
| November 20, 2020 Filed Nov 23, 2020 23:24 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
Exercise / conversionStock Options NQ (Right to Buy) · Derivative | 2,400 | $0.00 Strike: $34.02 | $0.00 |
DisclosureSEC source: 0001179110-20-011291 · edgar.xml · derivative · entry 8 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,400 shares Expires 2025-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan adopted by the reporting person on February 20, 2020. Read SEC document |
| November 20, 2020 Filed Nov 23, 2020 23:24 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
SaleCommon Stock | 2,400 | $105.01 | $252,034.08 |
DisclosureSEC source: 0001179110-20-011291 · edgar.xml · nonDerivative · entry 5 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,116 F3 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan adopted by the reporting person on February 20, 2020. F4 · price: The price reported in Column 4 is the average price of $105.0142. The sold price range between $105.00 to $105.03. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 20, 2020 Filed Nov 23, 2020 23:24 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
Exercise / conversionCommon Stock | 2,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-011291 · edgar.xml · nonDerivative · entry 4 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,516 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan adopted by the reporting person on February 20, 2020. Read SEC document |
| November 04, 2020 Filed Nov 4, 2020 22:48 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
SaleCommon Stock | 1,206 | $90.57 | $109,229.23 |
DisclosureSEC source: 0001179110-20-010828 · edgar.xml · nonDerivative · entry 6 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · In Trust with Wife Disclosed balance after: 229,113 F3 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan adopted by the reporting person on February 20, 2020. F6 · price: The price reported in Column 4 is the average price of $90.5715. The sold price range between $90.46 to $90.68. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.nature: Shares held in trust with Mr. Lipps' wife. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.